683 Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

683 Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.09M	Sell	1,450,000 -50,000	-3%	-$86K	0.15%	85
2026 Q1	$2.53M	Sell	1,500,000 -30,000	-2%	-$131K	0.13%	97
2025 Q4	$7.93M	Buy	1,530,000 +710,000	+87%	+$3.65M	0.34%	59
2025 Q3	$4.28M	Sell	820,000 -260,000	-24%	-$1.36M	0.22%	80
2025 Q2	$4.14M	Buy	1,080,000 +604,000	+127%	+$1.56M	0.27%	83
2025 Q1	$2.74M	Buy	476,000 +186,000	+64%	+$1.1M	0.19%	100
2024 Q4	$1.45M	Buy	+290,000	New	+$1.49M	0.09%	100
2023 Q2	–	Sell	-19,000	Closed	-$189K	–	171
2023 Q1	$189K	Sell	19,000 -10,519	-36%	-$74.4K	0.01%	165
2022 Q4	$205K	Sell	29,519 -670,481	-96%	-$3.83M	0.02%	159
2022 Q3	$3.74M	Sell	700,000 -300,000	-30%	-$1.8M	0.29%	78
2022 Q2	$3.99M	Buy	1,000,000 +500,000	+100%	+$1.72M	0.28%	82
2022 Q1	$2.22M	Buy	+500,000	New	+$1.99M	0.12%	116
2021 Q1	–	Sell	-216,818	Closed	-$1.49M	–	173
2020 Q4	$1.49M	Buy	216,818 +51,818	+31%	+$364K	0.07%	110
2020 Q3	$1.22M	Hold	165,000	–	–	0.09%	94
2020 Q2	$688K	Sell	165,000 -760,000	-82%	-$2.78M	0.06%	104
2020 Q1	$2.28M	Sell	925,000 -802,700	-46%	-$3.61M	0.27%	67
2019 Q4	$10M	Sell	1,727,700 -622,300	-26%	-$3.59M	1.15%	26
2019 Q3	$12.4M	Buy	2,350,000 +224,219	+11%	+$1.21M	1.38%	25
2019 Q2	$12.8M	Buy	2,125,781 +325,781	+18%	+$2.45M	1.16%	27
2019 Q1	$16.3M	Buy	1,800,000 +406,300	+29%	+$3.45M	1.47%	17
2018 Q4	$11.6M	Buy	1,393,700 +43,700	+3%	+$448K	0.7%	33
2018 Q3	$18.6M	Buy	1,350,000 +350,000	+35%	+$2.84M	1.21%	17
2018 Q2	$7.95M	Hold	1,000,000	–	–	0.54%	40
2018 Q1	$7.5M	Buy	1,000,000 +85,000	+9%	+$645K	0.66%	42
2017 Q4	$6.22M	Buy	915,000 +79,486	+10%	+$524K	0.52%	52
2017 Q3	$6.02M	Buy	835,514 +310,421	+59%	+$1.62M	0.63%	50
2017 Q2	$2.44M	Buy	+525,093	New	+$2.41M	0.36%	64

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

683 Capital Management's ALDX Position: Q2 2026 in Review

683 Capital Management reduced its Aldeyra Therapeutics (ALDX) stake by 3.3% in Q2 2026, selling an estimated $86K and leaving 1,450,000 shares worth $3.09M. The position accounts for 0.15% of the portfolio, ranked #85.

683 Capital Management first reported a position in ALDX in Q2 2017 and has held it in 27 quarters since. The position peaked at $18.6M in Q3 2018. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

683 Capital Management held 1,450,000 shares of Aldeyra Therapeutics worth $3.09M as of Q2 2026.
683 Capital Management sold 50,000 Aldeyra Therapeutics shares in Q2 2026, an estimated $86K.
Aldeyra Therapeutics made up 0.15% of 683 Capital Management's portfolio in Q2 2026, its #85 holding.
683 Capital Management first reported a position in Aldeyra Therapeutics in Q2 2017 and has held it in 27 quarters since.
683 Capital Management's Aldeyra Therapeutics position peaked at $18.6M in Q3 2018.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.